Comparative Pharmacology
Head-to-head clinical analysis: EQUAGESIC versus PLACIDYL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EQUAGESIC versus PLACIDYL.
EQUAGESIC vs PLACIDYL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Equagesic is a combination of aspirin and meprobamate. Aspirin irreversibly inhibits cyclooxygenase-1 (COX-1) and COX-2, reducing prostaglandin synthesis. Meprobamate potentiates GABA-A receptor activity, producing anxiolytic and sedative effects.
Ethchlorvynol is a sedative-hypnotic that depresses the central nervous system at the level of the brainstem and reticular formation, potentiating GABAergic inhibition. Its exact molecular mechanism is not fully defined.
Adults: 1 tablet (200 mg meprobamate, 25 mg ethoheptazine citrate, 325 mg aspirin) orally 3 or 4 times daily.
500 mg to 1000 mg orally at bedtime, as a hypnotic. Usual dose is 500 mg to 750 mg. Maximum dose 1000 mg.
None Documented
None Documented
Meprobamate: 10-12 hours in healthy adults, prolonged in liver disease; Aspirin: low doses 2-3 hours, anti-inflammatory doses 15-30 hours (saturable elimination).
Terminal elimination half-life is approximately 24 hours (range 10-40 hours), with prolonged elimination in hepatic impairment and overdose due to saturation of metabolism.
Meprobamate: renal (10% as unchanged drug, 80-90% as hydroxylated metabolites); Aspirin: renal (dose-dependent, 50-80% as salicyluric acid, 10% as unchanged salicylate at acidic pH).
Primarily renal excretion of metabolites; less than 1% excreted unchanged. Biliary/fecal elimination accounts for 30-40% of metabolites, with enterohepatic recycling.
Category C
Category C
Sedative-Hypnotic
Sedative-Hypnotic